Follow The Filings

FBIO Fortress Biotech Inc.

Health Care, filed as FORTRESS BIOTECH INC (COM NEW), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 1 Owner
  • Max 0.3%
  • $2.7M
  • 1 reduce

In 2026 Q2 James Silverman trimmed Fortress Biotech.

Who owns this now

Largest portfolio weights among holders, up to 0.3% (James Silverman, Opaleye Management). Not free-float ownership.

  1. James Silverman Reduce 0.25%

Who owns FBIO

Sorted by value, long equity only, as of 2026 Q2.

History
James Silverman, Opaleye Management 0.25%, was 0.39% Reduce −14.6% 890,000 $2.7M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by FBIO's executives, directors and 10% owners in the last 12 months, from their Form 4s

All FBIO insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales

No open-market buys or sales on file.

Also filed in the last 12 months, not counted as buying or selling: 10 stock grants.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 8.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 1.01,2.03,8.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13D/A — Filing Doc
424B3 Filing Doc
S-1 FORM S-1 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 1.01,2.03,3.02 Filing Doc
8-K 8.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc

Source: SEC EDGAR submissions, updated 10 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $59.66M $55.13M $61.24M
Gross profit * $33M $34.26M $40.32M
Gross margin * 55.3% 62.1% 65.8%
Net income -$60.64M -$46M $6.82M
Net margin * -101.6% -83.4% 11.1%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $117.02M $90.37M $123.84M
Total non-current assets * $50.5M $53.85M $61.71M
Total assets $167.53M $144.22M $185.55M
Total current liabilities $84.91M $71.4M $49.74M
Total non-current liabilities * $81.03M $74.47M $73.62M
Total equity $22.54M $22.74M $49.87M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$128.22M -$80.19M -$65.78M
Cash from investing -$2.1M -$15M $10.12M
Cash from financing $32.74M $70.64M $77.44M
Net change in cash -$97.59M -$24.55M $21.79M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.